• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by CONMED Corporation

    5/6/25 4:31:59 PM ET
    $CNMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $CNMD alert in real time by email
    DEFA14A 1 defa14a-34215_cnmd.htm DEFA14A
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

     

     

    Filed by the Registrant ☒

    Filed by a party other than the Registrant ☐

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement

     

    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) 

     

    ☐ Definitive Proxy Statement

     

    ☒ Definitive Additional Materials

     

    ☐ Soliciting Material under §240.14a-12 

    CONMED CORPORATION

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒ No fee required

     

    ☐ Fee paid previously with preliminary materials

     

    ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 

     

     

     

     

     

     

     

     

    Hollie Foust

    EVP, General Counsel and Corporate Secretary

    CONMED Corporation

    11311 Concept Blvd

    Largo, FL 33773

    (727) 392-6464

    www.CONMED.com

    John Ferrell

    EVP, Human Resources

    CONMED Corporation

    11311 Concept Blvd

    Largo, FL 33773

    (727) 392-6464

    www.CONMED.com

     

     

    May 6, 2025

     

    Via Email

     

    Re: ADDITIONAL MATERIALS RELATING TO THE PROXY STATEMENT FOR THE ANNUAL STOCKHOLDERS MEETING

     

    Dear CONMED Stockholders,

     

    At our upcoming Annual Stockholders Meeting on May 20, 2025, you are being asked to approve the Company’s 2025 Long-Term Incentive Plan (Proposal 3). We are providing additional detail regarding certain aspects of our equity strategy that we believe provide important context regarding our share usage relative to others in our industry. We encourage you to consider this information before voting your shares.

    Our Long-Term Incentive program relies heavily on options relative to peers, whose programs are weighted more heavily towards full value awards like Restricted Share Units (RSUs), which affects the dilution levels resulting from our program. Given CONMED’s heavy emphasis on stock options, and because many employees have not exercised their options, our total dilution levels are elevated. However, if you consider our total dilution on an adjusted basis – and only count unvested options as you would only count unvested full value shares – our total (full) dilution would be 12.3%, which compares favorably to the average dilution levels of our industry of 14.4%. We are sensitive to the dilutive impact our equity usage has on our stockholders; however, we believe stock options align participants with long-term absolute stockholder returns.

    We have been and will continue to be responsible in our equity usage. Our three-year average gross unadjusted burn rate of approximately 2.5% is below the three-year average burn rate within our industry of 3.79%, demonstrating our prudent deployment of equity. Further, we have sized the 3.6 million requested increase in the number of shares reserved for issuance under the Plan with the expectation that this pool will satisfy approximately three years’ worth of equity grant needs. We believe this time horizon is appropriate to ensure that our stockholders will have the opportunity to weigh in regarding our ongoing equity usage at regular intervals.

    Our Board encourages you to vote FOR the 2025 Long Term Incentive Plan. We hope this letter demonstrates our commitment to designing an executive compensation program that aligns with stockholder interests.

     

     

    If you have questions or would like to further discuss CONMED’s equity strategy, we would be happy to arrange a call to answer any questions and/or receive any feedback you may have. To schedule a call, please contact us at: [email protected]. We thank you for your consideration and continued support.

    Sincerely,

    A close up of a logo

AI-generated content may be incorrect.
    Hollie Foust
    EVP, General Counsel and Corporate Secretary
     
     
    A close-up of a signature

AI-generated content may be incorrect.
    John Ferrell
    EVP, Human Resources

     

     

     

    Get the next $CNMD alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $CNMD

    DatePrice TargetRatingAnalyst
    6/12/2025Buy → Hold
    Needham
    4/28/2025$55.00Buy → Hold
    Stifel
    2/6/2025$85.00 → $70.00Overweight → Neutral
    Analyst
    2/1/2024$119.00 → $129.00Buy
    Needham
    5/22/2023$140.00Buy
    CL King
    3/27/2023$124.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/21/2023$96.00Equal Weight
    Wells Fargo
    10/12/2022$85.00Hold
    Jefferies
    More analyst ratings

    $CNMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Bronson David M bought $97,322 worth of shares (1,350 units at $72.09), increasing direct ownership by 9% to 16,460 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/14/24 3:37:54 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Schwarzentraub Barbara J bought $99,873 worth of shares (1,442 units at $69.26) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/10/24 5:29:04 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Aronson Martha Goldberg bought $141,960 worth of shares (2,000 units at $70.98) (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      5/8/24 4:20:48 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • CONMED downgraded by Needham

      Needham downgraded CONMED from Buy to Hold

      6/12/25 7:52:09 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Stifel with a new price target

      Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00

      4/28/25 8:32:52 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED downgraded by Analyst with a new price target

      Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously

      2/6/25 7:05:01 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Schwarzentraub Barbara J converted options into 479 shares, increasing direct ownership by 12% to 4,344 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      6/4/25 5:42:25 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 4 filed by Director Kaye Mark

      4 - CONMED Corp (0000816956) (Issuer)

      6/4/25 5:41:24 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Director Concannon Brian converted options into 479 shares, increasing direct ownership by 5% to 10,116 units (SEC Form 4)

      4 - CONMED Corp (0000816956) (Issuer)

      6/4/25 5:40:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    SEC Filings

    See more
    • SEC Form 11-K filed by CONMED Corporation

      11-K - CONMED Corp (0000816956) (Filer)

      6/18/25 11:56:27 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

      8-K - CONMED Corp (0000816956) (Filer)

      6/16/25 4:31:25 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SD filed by CONMED Corporation

      SD - CONMED Corp (0000816956) (Filer)

      5/29/25 4:40:52 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Leadership Updates

    Live Leadership Updates

    See more
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Beta Bionics Announces the Appointment of Martha Goldberg Aronson as Chair of Its Board of Directors

      CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am

      2/9/21 4:01:00 PM ET
      $CSII
      $MEI
      $CNMD
      Medical/Dental Instruments
      Health Care
      Electrical Products
      Technology

    $CNMD
    Financials

    Live finance-specific insights

    See more
    • CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

      CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

      7/2/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces First Quarter 2025 Financial Results

      CONMED Corporation (NYSE:CNMD) today announced financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales of $321.3 million increased 2.9% year-over-year as reported and 3.8% in constant currency. Domestic revenue increased 4.2% year-over-year. International revenue increased 1.2% year-over-year as reported and 3.4% in constant currency. Diluted net earnings per share (GAAP) were $0.19, compared to diluted net earnings per share (GAAP) of $0.63 in the first quarter of 2024. Adjusted diluted net earnings per share(1) were $0.95, compared to adjusted diluted net earnings per share of $0.79 in the first quarter of 2024. "We had a good start t

      4/30/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • CONMED Corporation to Announce Second Quarter 2025 Financial Results on July 30, 2025

      CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic

      7/2/25 4:05:00 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Appoints LaVerne Council as Chair of the Board of Directors

      CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti

      5/21/25 7:03:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • CONMED Corporation Announces Quarterly Cash Dividend

      CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on May 20, 2025, payable on July 3, 2025, to all shareholders of record as of June 13, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based on certain as

      5/21/25 7:00:00 AM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $CNMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/13/24 4:22:22 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form SC 13G/A filed by CONMED Corporation

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      11/12/24 12:53:28 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by CONMED Corporation (Amendment)

      SC 13G/A - CONMED Corp (0000816956) (Subject)

      2/13/24 5:02:29 PM ET
      $CNMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care